SQI Diagnostics to Present at the European Bioanalysis Forum Open Symposium November 14-16, 2012
2012年11月13日 - 10:00PM
ビジネスワイヤ（英語）
SQI Diagnostics Inc. (TSX-V: SQD), a life sciences and
diagnostics company that develops and commercializes proprietary
technologies and products for advanced microarray diagnostics,
today announced that it has been chosen to present its Ig_PLEX
multiplexing technology and its accompanying platforms at the
European Bioanalysis Forum (EBF) Open Symposium being held in
Barcelona, Spain, November 14-16, 2012. The SQiDlite™ system, one
of SQI Diagnostics’ platforms to be highlighted, was developed to
address the multiplexed testing needs of clinical diagnostic
laboratories, pharmaceutical drug development and Contract Research
Organizations (CRO) performing bioanalytical and immunogenicity
testing.
Dr. Jaymie Sawyer, Vice President of Research and Development at
SQI Diagnostics will be presenting “Ig_ PLEX: A Novel Automated
Platform for Bioanalytics” in the Emerging and Innovative
Technologies Session on November 15, 2012.
The EBF is an annual meeting of the leaders of the bioanalytical
laboratories in the pharmaceutical and CRO markets in Europe and
beyond.
“This is a unique opportunity to educate the thought leaders of
the pharmaceutical and CRO industries about SQI Diagnostics’ unique
and innovative Ig_PLEX technology coupled with the power of the
SQiDlite System, that enable our customers to reduce cost and
increase efficiencies, accuracy, and reproducibility,” said Claude
Ricks, CEO of SQI Diagnostics. “We are honored to be asked by the
EBF to share SQI Diagnostics’ technology at this Symposium.”
About SQI Diagnostics
SQI Diagnostics is a life sciences and diagnostics company that
develops and commercializes proprietary technologies and products
for advanced microarray diagnostics. The Company’s proprietary
microarray tests and fully-automated systems are designed to
simplify protein and antibody testing workflow, increase
throughput, reduce costs and provide excellent data quality. For
more information, please visit www.sqidiagnostics.com.
For more information about SQiDliteTM and SQI Diagnostics’ suite
of biopharma and clinical diagnostic products and services please
visit www.sqidiagnostics.com, or contact SQI at:
sales@sqidiagnostics.com.
FORWARD-LOOKING INFORMATION
This press release contains certain forward-looking
statements, including, without limitation, statements containing
the words “may”, “plan”, “will”, “estimate”, “continue”,
“anticipate”, “intend”, “expect”, “believe”, “in the process”, “is
subject to” and other similar expressions which constitute
“forward-looking information” within the meaning of applicable
securities laws. Forward-looking statements reflect the Company's
current expectation and assumptions, and are subject to a number of
risks and uncertainties that could cause actual results to differ
materially from those anticipated. These forward-looking statements
involve risks and uncertainties including, but not limited to, the
ability of our patents to adequately protect our rights or permit
us to gain or keep any competitive advantage, and our ability to
market and sell our novel multiplexing technologies and detection
platforms. Such statements reflect the current views of the Company
with respect to future events and are subject to certain risks and
uncertainties and other risks detailed from time-to-time in the
Company’s ongoing filings with the securities regulatory
authorities, which filings can be found at
www.sedar.com. Actual results, events, and performance
may differ materially. Readers are cautioned not to place undue
reliance on these forward-looking statements. The Company
undertakes no obligation to publicly update or revise any
forward-looking statements either as a result of new information,
future events or otherwise, except as required by applicable
securities laws.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SQI Diagnostics (TSXV:SQD)
過去 株価チャート
から 11 2024 まで 12 2024
SQI Diagnostics (TSXV:SQD)
過去 株価チャート
から 12 2023 まで 12 2024
